As of 2024-07-27, the EV/EBITDA ratio of Alnylam Pharmaceuticals Inc (ALNY) is -210.66. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Alnylam's latest enterprise value is 30,044.76 mil USD. Alnylam's TTM EBITDA according to its financial statements is -142.62 mil USD. Dividing these 2 quantities gives us the above Alnylam EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.7x - 13.7x | 12.3x |
| Forward P/E multiples | 11.0x - 14.9x | 12.0x |
| Fair Price | (15.92) - (18.09) | (16.39) |
| Upside | -106.8% - -107.7% | -107.0% |
| Date | EV/EBITDA |
| 2024-07-26 | -210.66 |
| 2024-07-25 | -213.36 |
| 2024-07-24 | -212.12 |
| 2024-07-23 | -210.18 |
| 2024-07-22 | -211.33 |
| 2024-07-19 | -213.31 |
| 2024-07-18 | -212.31 |
| 2024-07-17 | -215.26 |
| 2024-07-16 | -223.96 |
| 2024-07-15 | -229.59 |
| 2024-07-12 | -233.43 |
| 2024-07-11 | -233.88 |
| 2024-07-10 | -230.99 |
| 2024-07-09 | -228.31 |
| 2024-07-08 | -228.64 |
| 2024-07-05 | -225.02 |
| 2024-07-03 | -222.94 |
| 2024-07-02 | -221.99 |
| 2024-07-01 | -218.18 |
| 2024-06-28 | -217.90 |
| 2024-06-27 | -221.45 |
| 2024-06-26 | -219.82 |
| 2024-06-25 | -215.37 |
| 2024-06-24 | -200.07 |
| 2024-06-21 | -149.34 |
| 2024-06-20 | -141.98 |
| 2024-06-18 | -138.84 |
| 2024-06-17 | -141.89 |
| 2024-06-14 | -144.63 |
| 2024-06-13 | -144.33 |
| 2024-06-12 | -143.44 |
| 2024-06-11 | -141.12 |
| 2024-06-10 | -138.50 |
| 2024-06-07 | -137.88 |
| 2024-06-06 | -134.80 |
| 2024-06-05 | -137.25 |
| 2024-06-04 | -135.21 |
| 2024-06-03 | -135.82 |
| 2024-05-31 | -134.03 |
| 2024-05-30 | -135.44 |
| 2024-05-29 | -132.70 |
| 2024-05-28 | -135.47 |
| 2024-05-24 | -133.43 |
| 2024-05-23 | -134.87 |
| 2024-05-22 | -136.22 |
| 2024-05-21 | -135.08 |
| 2024-05-20 | -135.63 |
| 2024-05-17 | -134.89 |
| 2024-05-16 | -136.50 |
| 2024-05-15 | -133.11 |